{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T10:34:49Z","timestamp":1782902089537,"version":"3.54.5"},"reference-count":0,"publisher":"Rockefeller University Press","issue":"6","content-domain":{"domain":["rupress.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[1992,6,1]]},"abstract":"<jats:p>10 patients with borderline and lepromatous leprosy were selected for a prolonged trial with recombinant interferon gamma (rIFN-gamma). Patients received 30 micrograms intradermally for six injections over a 9-d period, and then either 100 micrograms intradermally every 1 mo for 10 mo or every 2 wk for 5 mo (total, 1.2 mg). Erythema nodosum leprosum (ENL) was induced in 60% of the patients within 6-7 mo, as compared with an incidence of 15% per year with multiple drug therapy alone. The mean whole-body reduction in bacterial index over the first 6 mo was 0.9 log units. Cutaneous induration at the intradermal injection sites of greater than or equal to 15 mm predicted the development of a subsequent reactional state. Monocytes obtained from patients receiving the lymphokine demonstrated an increased respiratory burst and a 2.5-5.1-fold increase in tumor necrosis factor alpha (TNF-alpha) secretion in response to agonists. Patients in ENL had an even higher release of TNF-alpha from monocytes as well as high levels of TNF-alpha in the plasma (mean, 2,000 pg\/ml). Thalidomide therapy was required to treat the systemic manifestations of ENL. Control of toxic symptoms with thalidomide was associated with a 50-80% reduction in agonist-stimulated monocyte TNF-alpha secretion. IFN-gamma enhanced the monocyte release of TNF-alpha by 3-7.5-fold (agonist dependent) when added to patient's cells in vitro, and this could be suppressed by the in vitro addition of 10 micrograms\/ml of thalidomide.<\/jats:p>","DOI":"10.1084\/jem.175.6.1729","type":"journal-article","created":{"date-parts":[[2004,6,24]],"date-time":"2004-06-24T07:56:10Z","timestamp":1088063770000},"page":"1729-1737","update-policy":"https:\/\/doi.org\/10.1084\/jem.crossmarkpolicy","source":"Crossref","is-referenced-by-count":114,"title":["Prolonged treatment with recombinant interferon gamma induces erythema nodosum leprosum in lepromatous leprosy patients."],"prefix":"10.1084","volume":"175","author":[{"given":"E P","family":"Sampaio","sequence":"first","affiliation":[{"name":"Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A L","family":"Moreira","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E N","family":"Sarno","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A M","family":"Malta","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G","family":"Kaplan","sequence":"additional","affiliation":[{"name":"Laboratory of Cellular Physiology and Immunology, Rockefeller University, New York, New York 10021."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"291","published-online":{"date-parts":[[1992,6,1]]},"container-title":["The Journal of experimental medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/175\/6\/1729\/1673544\/1729.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/rupress.org\/jem\/article-pdf\/175\/6\/1729\/1673544\/1729.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,25]],"date-time":"2023-07-25T04:46:21Z","timestamp":1690260381000},"score":1,"resource":{"primary":{"URL":"https:\/\/rupress.org\/jem\/article\/175\/6\/1729\/57447\/Prolonged-treatment-with-recombinant-interferon"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1992,6,1]]},"references-count":0,"journal-issue":{"issue":"6","published-print":{"date-parts":[[1992,6,1]]}},"URL":"https:\/\/doi.org\/10.1084\/jem.175.6.1729","relation":{},"ISSN":["0022-1007","1540-9538"],"issn-type":[{"value":"0022-1007","type":"print"},{"value":"1540-9538","type":"electronic"}],"subject":[],"published":{"date-parts":[[1992,6,1]]}}}